亚星首页_亚星(中国)官网

Hanyu Medical

Innovative researchers in the
field of structural heart
disease intervention devices

Guarding Life, Inspiring a Healthier World

The company is committed to its mission of “Guarding Life, Inspiring a Healthier World.”
It focuses on the research, development, manufacturing, and commercialization of interventional devices for structural heart disease, and operates several subsidiaries, including Hongyu Medical, Hanyu Singapore, and Hanyu Guangdong.

In the field of structural heart disease intervention, the company’s innovative medical device — the ValveClamp® Mitral Valve Repair System — received official approval from the National Medical Products Administration (NMPA) in September 2023, becoming the first domestically approved transcatheter mitral regurgitation repair device in China.
As of 2025, the product has entered commercial sales in Indonesia, Thailand, Singapore, Vietnam, and Colombia.

The company’s R&D pipeline covers a broad range of interventional therapies for structural heart diseases.
Among them, the ReAces® Atrial Septal Defect Occluder has completed patient enrollment in its registration clinical trial and entered the follow-up stage, while the ValveClasp® Transcatheter Mitral Valve Repair System was included in China’s Special Review Procedure for Innovative Medical Devices in 2023 and is currently undergoing clinical evaluation.

The company’s products have been applied in over 60 hospitals across China and are being commercialized in more than 20 countries worldwide, accelerating the global presence of China’s innovative medical technologies.

Hanyu Medical has been deeply engaged in the field of structural heart disease, committed to providing safe, effective, and accessible integrated solutions to address significant unmet clinical needs in China and around the world, thereby improving patients’ survival and quality of life.

Looking ahead, Hanyu Medical will continue to focus on addressing unmet clinical needs in structural heart disease through continuous technological innovation and global commercialization, driving the advancement of China’s high-end medical device industry and contributing to better patient outcomes and longer lives.

2016

The company was established in
100+

Clinical applications in
10+

Commercial sales in

Development History

Witness Hanyu Medical's
innovative development path

2024

2023

2022

2021

2020

2018

2017

2016

Swipe to see more

Development History

Witness Hanyu Medical's
innovative development path

2024

· A total of 89 hospitals have successfully performed surgeries, with over 300 implantation cases carried out domestically throughout the year

2024

· Hanyu Medical has obtained sales certificates in Indonesia, Thailand, and Singapore respectively

· Indonesia Medical Device Product Circulation License

· Thai TFDA Medical Device Registration Certificate

· Singapore Medical Device Sales License

April

· Awarded as a key service unicorn enterprise in Shanghai

October

· National high-tech enterprise

(Ministry of Industry and Information Technology of the People's Republic of China)

2023

August

· The registration and clinical study of ReAces, a puncturable atrial septal defect occluder, have been completed

September

· Valveclamp successfully obtained the Medical Device Registration Certificate from the National Medical Products Administration

November

· Valveclamp Launches the "the Belt and Road" Indonesia Heart Care Tour

2022

October

· Obtained IS013485:2016 Medical Device Quality Management System Certification

2021

March

· Series D financing of 455 million yuan

· The company's valuation is 7.455 billion yuan

July

· Puncture occluder Reaces completed Fim test enrollment

October

· ValveClasp enters the clinical stage of FIM via the femoral mitral valve clamp

· Rated as a high-tech enterprise by the Shanghai Science and Technology Commission

2020

August

· Series D financing of 500 million yuan

· The company is valued at 3 billion yuan

December

· Convene the founding meeting of a limited liability company and complete the reform of the shareholding system

2018

January

· Series A financing of 43.64 million yuan, company valuation of 305 million yuan

July

· The successful completion of the world's first transapical mitral valve clip procedure marks a new stage in the treatment of mitral regurgitation in China

October

· Successfully completed 12 exploratory clinical trials (first-in-man), achieving a 100% success rate and 100% efficacy rate,
· Valveclamp won the Best Innovation Award at the Cardiovascular Innovation Conference ICI2018.

2017

January

· Angel round financing was successful, and the company's valuation was approximately 60 million yuan

May

· Pre-a round financing of 11.8 million yuan, the company's valuation is 105 million yuan

2016

December

· Shanghai Hanyu Medical Technology Co., Ltd. was established